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Several mouse models have already proved valuable for investi-
gating hypertrophic responses to cardiac stress. Here, we charac-
terize one caused by a well defined single copy transgene,
RenTgMK, that genetically clamps plasma renin and thence angio-
tensin II at high levels. All of the transgenic males develop con-
centric cardiac hypertrophy with fibrosis but without dilatation.
Over half die suddenly aged 6–8 months. Telemetry showed
disturbances in diurnal rhythms a few days before death and, later,
electrocardiographic disturbances comparable to those in humans
with congestive heart failure. Expression of seven hypertrophy-
related genes in this and two categorically different models (lack
of atrial natriuretic peptide receptor A; overexpression of calse-
questrin) were compared. Statistical analyses show that ventricular
expressions of the genes coding for atrial natriuretic peptide, 
myosin heavy chain, medium chain acyl-CoA dehydrogenase, and
adrenomedullin correlate equally well with the degree of hyper-
trophy, although their ranges of expression are, respectively, 50-,
30-, 10-, and 3-fold.
Hypertrophy of cardiac myocytes, a response to increasedcardiac stress, can be induced by many different physiolog-
ical and molecular stimuli (1), as illustrated by a variety of
experimental models in mice, including genetic modification (2),
pressure overload (3), drug treatment (4), and strain-dependent
genetic modifiers (5, 6). Despite the variety of methods used to
induce the hypertrophy, the resulting animals share a common
feature: re-expression of a fetal-like gene program. This program
shift includes changes in secreted and contractile proteins, ion
channels, and energy metabolism. Yet recent studies using
differential display (7) and microarray technology (4, 8, 9) have
shown no single program of gene expression common to all
models, making further comparative studies desirable.
Toward this end, we have developed and characterized several
genetic models of cardiac hypertrophy mediated through differ-
ent pathways and of differing severity. Two have been described
previously. First, mice that lack the guanylyl cyclase-type atrial
natriuretic peptide receptor (NPRA) develop mild hyper-
tension, 9 mmHg (1 mmHg  133 Pa) greater than WT
controls (10); and dilated cardiac hypertrophy that is indepen-
dent of and disproportionate to their elevated blood pressure,
demonstrating a direct role of NPRA in the progression of
cardiac hypertrophy (11). A considerably more severe cardiac
hypertrophy is generated in mice with transgenic overexpression
of a cDNA coding for the sarcomeric calcium binding protein,
calsequestrin (CSQ) (12). The CSQ transgenic mice develop
severe dilated cardiomyopathy and all die within 16 weeks of
age (13).
In the present paper we describe and characterize a third
model of (intermediate) cardiac hypertrophy without dilatation
in which about half of the males die between 6 and 8 months of
age. The hypertrophy is caused by a high plasma level of active
renin, and thence of angiotensin II (Ang II), resulting from a
‘‘genetically clamped’’ transgene (RenTgMK). This transgene is
clamped because it produces physiologically active renin at a
constant level that is insensitive to cardiovascular homeostatic
signals and is expressed in the liver, an organ that is uninvolved
in blood pressure regulation (14). We compare the RenTgMK
model with the two previous models by using precision quanti-
tative RT-PCR to determine the expression of a panel of genes,
each relevant to cardiac myocyte function. The high sensitivity
of this molecular phenotyping procedure allows precise data to
be obtained with samples from individual animals rather than
pooled samples. Consequently we have been able to determine
the degree to which differences in gene expression correlate with
differences in hypertrophy between the three models and with
differences between individual mice within the same model.
Experimental Procedures
Our procedure for generating renin transgenic mice has been
described (14). The transgene, RenTgMK, used in the present
work consists of (i) a liver-specific albumin promoterenhancer
(15), (ii) a 20-bp oligonucleotide insert in the 5 UTR to increase
its length (16), (iii) a synthetic mouse renin cDNA, and (iv) a
rabbit -globin 3 UTR. The synthetic renin gene includes an
N-glycosylation site for increased stability and is engineered so
that processing from prorenin to renin can be efficiently
achieved in hepatic or other cells by the ubiquitous enzyme furin
(17). Single-copy chosen-site gene targeting (18) was used to
insert the RenTgMK into the apolipoprotein locus between the
Apoa1 and Apoc3 genes.
For PCR-based genotyping of the RenTgMK mice we
use three primers: primer 1, 5-TGGGATTCTAACCCTGA-
GGACC-3; primer 2, 5-CACAGATTGTAACTGCAAATCT-
GTCG-3; and primer 3, 5-GTTCTTCTGAGGGGAT-
CGGC-3.
The mice used in the present study had one copy of the
RenTgMK and were 4- to 8-month-old males. For comparative
studies between lines, age-matched male mice were used.
The NPRA mice (10) and CSQ transgenic mice (12, 13)
have been described.
Blood pressures were measured on unanesthetized mice by a
computerized tail cuff system (19). Transthoracic M-mode echo-
cardiography was performed on unanesthetized 6 month old
mice by using a HDI 5000CV echocardiograph machine with a
10.5-MHz frequency probe (ATL Ultrasound).
In vivo physiological monitoring of 4-month-old RenTgMK
and WT mice was performed by using biosensors (TA10ETA-
F20, Data Sciences International, Minneapolis) to measure
temperature, activity, and electrocardiographic waveforms. The
biosensor is surgically placed in the peritoneal area and
the attached s.c. insulated wire electrodes are positioned in the
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upper and left lower thorax analogous to a lead II configuration.
Data were collected at 1,000 samples per s for 10 consecutive
seconds at intervals of 5 min and collected by using PHYSIOSTAT
3.22 software (Data Sciences International). The electrocardio-
graphic waveforms were analyzed for rhythm, morphology, and
intervals [QRS, R–R, QT, and SD between normal intervals
(SDNN)] by using PHYSIOSTAT 3.22 software. Microvolt T wave
alternans were detected by using custom designed software
based on the method described by Nearing and Verrier (20).
Quantitative RT-PCR was performed with an Applied Bio-
systems 7700 Sequence Detection System by using total RNA
purified from the left ventricle with the primers and probes listed
in Table 2, which is published as supporting information on the
PNAS web site; some of these have been described (21).
For general histology, 5-m-thick paraffin sections were
stained with hematoxylin and eosin or with Masson’s trichrome
reagents.
All experiments were conducted with 4- to 8-month-old male
mice and were approved by the Institutional Animal Care and
Use Committee of the University of North Carolina, Chapel Hill.
Statistical analyses were performed with JMP software (SAS
Institute, Cary, NC).
Results
Cardiac Hypertrophy in RenTgMK Mice. We have previously re-
ported a method for generating mice with genetically clamped
renin transgene expression in their livers (14). The transgene is
inserted as a single copy into the ApoA1ApoC3 locus that is
active in the liver. Our previous publication focused on the blood
pressures and renal phenotypes of mice carrying our simplest
transgene, designated RenTgKC. The present study focuses on
cardiac hypertrophy with male mice that have a modified form
of this renin transgene. The modification consists of the insertion
of a random 20-bp oligonucleotide sequence into the 5 UTR of
the transgene to increase its translation efficiency, as described
by Marilyn Kozak (16). We refer to this modified transgene
and mouse line as RenTgMK. The RenTgMK mice have in-
creased production of renin relative to mice with the unmodified
RenTgKC. Their natural renin genes are WT.
Fig. 1A shows that the RenTgMK mice have significantly
elevated blood pressure compared to WT littermates (146  3
mmHg for the RenTgMK vs. 121  4 mmHg for the WT, P 
0.0001). Fig. 1B shows that the mice develop cardiac hypertrophy
as judged by an increase in left ventriclebody weight (BW) ratio
compared to controls (5.2  0.2 for the RenTgMK vs. 3.5  0.2
for the WT, P  0.0001).
Histological examination of the hearts of the RenTgMK mice
confirms the cardiac hypertrophy (Fig. 2 A and B), as judged by
an increase in cardiac myocyte cross-sectional area. Masson’s
trichrome staining revealed generalized fibrosis that was more
predominant in the posterior wall of the left ventricle. The WT
controls had no pathological fibrosis (Fig. 2 C–F).
To assess the cardiac function of the RenTgMK mice, we
performed echocardiography on conscious 6-month-old ani-
mals. As shown in Table 1, the RenTgMK mice display a
significant decrease in left ventricular end systolic dimension
(LVESD) coupled with an increase in cardiac function (as
assessed by fractional shortening). Heart rate was also increased
in the RenTgMK mice and likely accounts for the modest, yet
significant increase in fractional shortening. Taken together,
these parameters indicate that at 6 months these RenTgMK mice
have concentric hypertrophy, without ventricular dilation or
overt heart failure.
Electrocardiographic Monitoring of Sudden Death in RenTgMK Mice.
Approximately 60% of RenTgMK male mice die suddenly
between 6 and 8 months of age. To investigate the potential
Fig. 1. (A) Mean blood pressure of 6-month-old RenTgMK and WT control
mice measured by a computerized tail cuff method. (B) Left ventricleBW ratio
of 8-month-old RenTgMK and WT control mice.
Fig. 2. Hematoxylineosin stained sections of the left ventricle of 8-month-
old WT (A) and RenTgMK (B) mice. (C–F) Masson’s trichrome stained sections
of left ventricle of 8-month-old WT (C and E) and RenTgMK (D and F) mice.
Table 1. Echocardiography in WT and RenTgMK mice
WT RenTgMK P value
LVEDD, mm 3.3  0.1 3.1  0.1 0.192
LVESD, mm 1.3  0.1 0.9  0.1 0.022*
FS, % 61.2  2.1 69.5  2.7 0.036*
IVS, mm 1.0  0.1 1.2  0.1 0.059
PW, mm 0.9  0.1 1.0  0.1 0.109
HR, bpm 600  26 692  26 0.034*
VcFc, circ per s 4.33  0.2 6.17  0.5 0.010*
LVEDD, left ventricular end diastolic dimension; LVESD, left ventricular end
systolic dimension; FS, fractional shortening (LVEDD-LVESD)LVEDD; IVS, in-
traventricular septal thickness; PW, posterior wall thickness; HR, heart rate;
bpm, beats per minute; circsec, circumference per second; VcFc, heart rate-
corrected mean velocity of circumferential fiber shortening calculated as FS
divided by ejection time multiplied by the square root of the R–R interval. n 
6 for each group.
*Denotes a significant difference between RenTgMK and WT mice.











cause of these deaths, we used continuous telemetric recording
of electrocardiographic waveforms, activity, and body temper-
ature in four 4-month-old RenTgMK mice and age-matched
WT controls. During the course of our studies, one of the
RenTgMK mice (mouse 1) died at age 5 months while being
monitored, and a second (mouse 2) was monitored until
moribund. Fig. 3 A and B illustrates the continuous and diurnal
heart rates that were recorded in each of these mice, respec-
tively. The normal diurnal variation in heart rate in mouse 1
subsided approximately 4 days before death (Fig. 3A) and was
correlated with a decrease in body temperature and activity
(data not shown). Changes in the diurnal patterns of the
recorded parameters were not observed in the age-matched
WT mice. In both mice, we found a significant lengthening of
the QT interval that corresponded to a prolonged and pro-
gressive bradycardia (Fig. 3 C and D). We calculated the R–R
interval, the P–R interval, and the SD between normal inter-
vals (SDNN) at the times depicted in Fig. 3 C and D and at
equivalent times in WT mice. We found a significant length-
ening of the R–R interval in the RenTgMK mice as compared
to WT controls (144.8 ms  11.6 for RenTgMK versus 112.3
ms  1.9 for WT, P  0.02). In both RenTgMK mice, we
observed a prolongation of the P–R interval and progressive
QRS widening, indicating conduction abnormalities in the
atrioventricular node and ventricles (Fig. 3 C and D). The
RenTgMK mice also showed a significant decrease in heart
rate variability compared to WT controls. The SDNN values
were 1.54  0.32 for RenTgMK mice compared to 3.27  0.43
Fig. 3. Electrocardiographic measurements in RenTgMk mice. (A) Mouse 1; 1-h moving averages of heart rate waveforms recorded for 15 consecutive days
before death. Diurnal heart rate changes are detectable until 4 days before death. Shaded boxes represent dark cycle, and open boxes represent light cycle.
(B) Mouse 2; 1-h moving averages of heart rate wave forms recorded until mouse was moribund. (C and D) Mouse 1 (C) and mouse 2 (D); individual
electrocardiographic recordings monitored before death depicting progressive bradycardia. Solid black lines depict lengthening QT interval. (E and F) Mouse
1 (E) and mouse 2 (F); presence of alternating patterns of electrical activation and recovery.
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for WT mice (P  0.004). A few hours before the terminal
death event, alternating electrical conduction patterns similar
to microvolt T wave alternans in humans were recorded during
sinus rhythm (Fig. 3 E and F).
Molecular Phenotype of Cardiac Hypertrophy. To characterize the
molecular phenotype of the RenTgMK mice, we used quanti-
tative RT-PCR on left ventricular total RNA to determine the
expression of seven genes previously shown or suspected to be
involved in the progression of cardiac hypertrophy. These in-
clude genes that change expression during normal development
[ myosin heavy chain (-MHC), -MHC, and medium chain
acyl-CoA dehydrogenase (MCAD)], genes that are widely rec-
ognized as markers of cardiac hypertrophy [atrial natriuretic
peptide (ANP) and brain natriuretic peptide (BNP)], and genes
that have recently been implicated in cardiac hypertrophy [trans-
forming growth factor  1 (TGF-1) and adrenomedullin
(AM)]. We used -actin as an internal standard.
As expected and shown in Fig. 4A, the cardiac myocytes of the
RenTgMK mice exhibit a switch toward the fetal-like state as
indicated by a significant (P  0.006) increase in the ratio of
expression of the fetal type MHC, -MHC, relative to that of the
adult-type MHC, -MHC [expression of -MHC alone de-
creased but did not reach significance; P  0.15]. Expression
of MCAD, which decreases when cells shift their energy
source from fatty acids to carbohydrates, was decreased in the
RenTgMK mice relative to WT but did not reach statistical
significance (Fig. 3B; P  0.12). The RenTgMK mice show
striking increases in the expression of classical markers of cardiac
hypertrophy, ANP (Fig. 3C; P  0.0001), and BNP (Fig. 3D; P 
0.0001).
TGF-1 is a multifunctional growth factor that becomes
elevated in pathological fibrosis (22, 23), and recent studies have
shown that TGF-1 is an important mediator of cardiac hyper-
trophy induced by Ang II (23, 24). Because, in the RenTgMK
mice, active renin overexpression results in increased levels of
Ang II (14), we expected and found that TGF-1 expression in
the ventricles of the RenTgMK mice was increased, to almost
three times WT controls (Fig. 3E; P  0.008).
AM is a recently identified potent vasodilator that is required
for normal cardiovascular development (25). This peptide hor-
mone also has growth regulatory properties in cultured cardiac
myocytes and has been implicated in the homeostatic response
to hypertension and cardiac hypertrophy in both rodent models
and human patients (26). It is strongly expressed in the heart and
vasculature and its absence in a gene targeted knockout model
leads to embryonic lethality associated with hydrops fetalis and
cardiovascular defects (25). We found a significant decrease
(Fig. 3F; P  0.0001) in AM gene expression in the left ventricle
of the RenTgMK mice to about one-third compared to WT
controls.
Comparative Molecular Phenotyping. For reasons considered in
more detail in the discussion, we next compared expression of
the same seven genes in the RenTgMK mice to expression in
mice lacking the natriuretic peptide receptor A (NPRA)
and in transgenic mice overexpressing calsequestrin (CSQ) in
their hearts. The mice lacking NPRA develop hypertrophy
generally less than but overlapping that in the RenTgMK mice
(heart weightBW ratio is 127% of WT for NPRA mice
compared to 136% of WT for the RenTgMK mice). The CSQ
transgenic mice develop hypertrophy generally greater than but
again overlapping that of the RenTgMK mice (heart weightBW
ratio is 174% of WT). Because of the sensitivity of quantitative
RT-PCR, the molecular phenotypes (21) of the 15 individual
mice that we used in this comparison could be determined
without pooling samples. The comparison showed that four of
the seven genes tested had left ventricular expression changes
significantly and proportionality correlated with the degree of
hypertrophy regardless of the method of induction (Fig. 5). [The
other three genes did not show significant correlations across all
of the three models: -MHC, P  0.21; BNP, P  0.82; TGF-1,
P  0.26.] Not surprisingly, ventricular ANP expression was
significantly (P  0.0001, r2  0.78) and positively correlated
proportionately over a 100-fold range with the degree of hyper-
trophy, as was expression of -MHC (P  0.0003, r2  0.65). Left
ventricular expression of MCAD (P  0.0001, r2  0.72) was
proportionately correlated over a 10-fold range with the degree
of hypertrophy but in the opposite (negative) direction. AM (P 
0.0001, r2  0.77) was likewise proportionately and negatively
correlated over a 3-fold range with the degree of hypertrophy.
We conclude that the proportionality of the response to hyper-
trophy of the four genes is equivalent (as judged by r2) and
independent of the inducer although the magnitude of the
responses range from 100-fold to 3-fold.
Discussion
We describe here a genetically clamped renin transgene mouse,
RenTgMK, in which active renin is secreted from the liver
independently of renal or other homeostatic cardiovascular
control mechanisms. The RenTgMK mice are consequently the
genetic equivalent of chronic physiological infusion of Ang II
with a minipump, but with the advantage of being caused by a
Fig. 4. Quantitative gene expression determined by an Applied Biosystems
7700 real-time RT-PCR. Total RNA from the left ventricle of 8-month-old WT
and RenTgMK mice was used with the primer and probes sets depicted in a
Table 2. (A) Ratio of -MHC-MHC. (B) MCAD. (C) ANP. (D) BNP. (E) TGF-1.
(F) AM.











genetic change that is lifelong and noninvasive. We show that the
RenTgMK mice have high blood pressure and concentric cardiac
hypertrophy. By 8 months of age, severe cardiac remodeling and
fibrosis accompany the cardiac hypertrophy, as evidenced by
histological examination.
Several genetically engineered animal models that directly
target the mechanical, contractile, or conduction properties of
cardiomyocytes exhibit sudden cardiac death and lethal arrhyth-
mias (27–29). In contrast, the cardiac hypertrophy and sudden
death of the RenTgMK mice is hormonally induced through
elevated circulating levels of Ang II. Telemetric recordings
suggest that the sudden death we observe in some of the
RenTg1MK mice is presaged by disturbances in the normal daily
decreases in heart rate, body temperature, and activity. The
electrocardiograms also demonstrated progressive slowing of the
heart, increased intramyocardial conduction abnormalities,
lengthening of the R–R and QT interval, decreased SD between
normal intervals (SDNN), and the appearance of T-wave alter-
nans. These changes indicate a rapidly progressing myocardial
dysfunction and are analogous to clinical features shared
by humans with congestive heart failure at high risk for death
(30, 31).
To further characterize the cardiac hypertrophy of the RenT-
gMK mice we used quantitative RT-PCR assay to quantitatively
assess changes in the expression of a chosen panel of seven genes
variously implicated with hypertrophy. These studies were fo-
cused on male mice. However, we note that our previous
molecular phenotyping studies (21) and current preliminary
studies with RenTgMK female mice show that, as in humans,
some genes are sexually dimorphic in their responses to cardiac
hypertrophy. In male RenTgMK mice, we find five of the seven
genes tested (-MHC, ANP, BNP, TGF-1, and AM) show
significant changes (P  0.01) in ventricular expression in the
RenTgMK mice. The other two (-MHC and MCAD) show
changes but they do not reach significance (P  0.1). However,
the data clearly show that the cardiac hypertrophy in the
RenTgMK mice is accompanied by the well known shift to a
fetal-like pattern of gene expression.
The RenTgMK mice develop a substantial level of cardiac
hypertrophy as a result of an enhanced synthesis of active
renin. Consequently, their cardiomyocytes are exposed to two
hypertrophic stimuli: an increased mechanical load (25
mmHg) and an increased level of plasma Ang II. As an
approach to identifying and comparing cellular responses that
are present in all hypertrophic cardiomyocytes irrespective of
the means of inducing the hypertrophy, we therefore compared
the molecular phenotypes of the RenTgMK mice with those of
two other categorically different models. Mice lacking NPRA
were chosen as one of these models because they have modest
hypertrophy due to an increased mechanical load (9 mmHg)
combined with absence of the moderating effects of the
natriuretic peptides. The CSQ transgenic mice were chosen
because they have more severe hypertrophy although they have
blood pressures lower than WT; their stimulus is an intracel-
lular disturbance in calcium signaling pathways. The inducers
of the hypertrophy are therefore categorically different in the
three models.
The results of the comparison are clear: the ventricular
expressions of ANP (P  0.0001) and -MHC (P  0.0003) are
positively correlated with the degree of cardiac hypertrophy in
the three models. Ventricular expressions of MCAD (P 
0.0001) and of AM (P  0.0001) are likewise highly correlated
in all three models, although in this case negatively. A caveat is
necessary, however, for the AM gene, because our preliminary
unpublished work shows that it does not change expression with
the hypertrophy that develops in RenTgMK females. Neverthe-
less, we conclude that these four genes in males (three in
females) are likely to be obligate responders to any hypertrophic
stimuli. The proportionality of the responses of these four genes
to the three inducers are equivalent (as judged by their very
similar r2 values following bivariate analysis of hypertrophy
versus expression). This equal proportionality suggests that they
all receive and respond to some common signals. On the other
hand, the magnitude of the induced responses are not equivalent,
because they range from 50-fold (for ANP) to 30-fold (for
-MHC) to 10-fold (for MCAD) to 3-fold (for AM), suggesting
that the genes are differently sensitive to these signals.
In conclusion, we emphasize that RenTgMK is a simple
transgene with a well defined mode of action that is useful
for inducing concentric cardiac hypertrophy, accompanied in
males by fibrosis and a shift of cardiomyocytes to a fetal-like
pattern of gene expression. Moreover, we conclude that the
pathological manifestation of the sudden death in the RenTgMK
mice, which includes loss of diurnal rhythms, lengthening of the
QT interval, loss of heart rate variability, and the appearance of
T-wave alternans, is similar to what is seen in the failing human
heart.
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